Usefulness of pT1 substaging in papillary urothelial bladder carcinoma.
Patriarca C, Hurle R, Moschini M, Freschi M, Colombo P, Colecchia M, Ferrari L, Guazzoni G, Conti A, Conti G, Lucianò R, Magnani T, Colombo R.
Diagn Pathol. 2016 Jan 20;11:6. doi: 10.1186/s13000-016-0466-6.
PMID:26791567
Papillary Urothelial Carcinoma.
Gupta S, Lipworth R, Mynderse LA.
Mayo Clin Proc. 2021 Nov;96(11):2746-2747. doi: 10.1016/j.mayocp.2021.08.022.
PMID:34736606
Prognosis of carcinoma in situ according to the presence of papillary bladder tumors after bacillus Calmette-Guerin immunotherapy.
Kim SJ, You D, Jeong IG, Song C, Hong B, Kim CS, Ahn H, Hong JH.
J Cancer Res Clin Oncol. 2019 Aug;145(8):2131-2140. doi: 10.1007/s00432-019-02956-6. Epub 2019 Jun 21.
PMID:31227894
Re: final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guerin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance.
Wood DP.
J Urol. 2014 Feb;191(2):348-9. doi: 10.1016/j.juro.2013.10.133. Epub 2013 Oct 29.
PMID:24411846
Clinicopathological Review of Micropapillary Urothelial Carcinoma.
Benign and low-grade papillary lesions of the urinary bladder: a review of the papilloma-papillary carcinoma controversy, and a report of five typical papillomas.
Eble JN, Young RH.
Semin Diagn Pathol. 1989 Nov;6(4):351-71.
PMID:2692107
Prognostic significance of minor high grade component in non-invasive papillary urothelial carcinoma of urinary bladder: (A study of 273 consecutive cases over a period of 3 years).
Syed M, Mushtaq S, Loya A, Hassan U, Mir K, Hussain M, Hameed M, Sheikh UN.
Ann Diagn Pathol. 2023 Apr;63:152079. doi: 10.1016/j.anndiagpath.2022.152079. Epub 2022 Dec 13.
PMID:36549142
Coexistence of Malakoplakia and Papillary Urothelial Carcinoma of the Urinary Bladder.